Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
TCR2 Therapeutics
Biotech
Adaptimmune absorbs TCR² to extend cash runway, broaden pipeline
The combined entity is trading under Adaptimmune’s Nasdaq ticker and is led by its CEO Adrian Rawcliffe.
James Waldron
Mar 6, 2023 9:30am
Layoffs still battering biotech, with Big Pharmas piling on pain
Feb 1, 2023 10:50am
TCR² first began layoffs back in August
Jan 13, 2023 11:00am
TCR2's cell therapy racks up 22% response rate in solid tumors
Sep 28, 2022 9:40am
TCR2 taps ElevateBio to manufacture T-cell therapy for phase 2
Nov 10, 2020 8:00am
TCR2's T-cell therapy curbs solid tumors in early phase 1 data
Jul 27, 2020 10:45am